Re: Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

noretreat

Rank: Vice President [?]

Points: 1412 [?]

Votes: 14 Score: 3.2 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

in response to

Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

BearDownAZ

posted on Aug 06, 2019 09:11AM

I wonder what the specific terms are regarding the $15 million for development. That could fund a significant part of the road to an NDA.

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply